Hindustan Bio Sciences Intrinsic Value
Hindustan Bio Sciences (HINDBIO) median intrinsic value is ₹5.00 from 2 valuation models (range ₹4–₹5), vs current price ₹9.19 — -45.6% downside (Trading Above Calculated Value), margin of safety -83.8%. For current market price and key ratios, visit Hindustan Bio Sciences share price chart.
HINDBIO Valuation Methods Summary — DCF, Graham Number & P/E
Hindustan Bio Sciences intrinsic value across 2 models vs current price ₹9.19 — upside/downside and value range per method. Browse HINDBIO complete financial for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹5.00 | ₹4.50 - ₹5.50 | -45.6% | Book Value/Share: ₹5.00, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹4.00 | ₹3.60 - ₹4.40 | -56.5% | Revenue/Share: ₹5.00, P/S: 0.8x |
HINDBIO Intrinsic Value vs Market Price — All Valuation Models
Hindustan Bio Sciences fair value range ₹4–₹5 vs current market price ₹9.19 across 2 valuation models. Compare with HINDBIO stock valuation models to assess whether the stock is under or overvalued.
HINDBIO Intrinsic Value Analysis — Undervalued or Overvalued?
Hindustan Bio Sciences median intrinsic value ₹5.00, current price ₹9.19 — Trading Above Calculated Value by 45.6%, margin of safety -83.8%.
What is the intrinsic value of HINDBIO?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Hindustan Bio Sciences (HINDBIO) is ₹5.00 (median value). With the current market price of ₹9.19, this represents a -45.6% variance from our estimated fair value.
The valuation range spans from ₹4.00 to ₹5.00, indicating ₹4.00 - ₹5.00.
Is HINDBIO undervalued or overvalued?
Based on our multi-method analysis, Hindustan Bio Sciences (HINDBIO) appears to be trading above calculated value by approximately 45.6%.
HINDBIO Financial Health — Key Ratios vs Industry Benchmarks
Hindustan Bio Sciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.33 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 3.00 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Operating Margin | 7.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.33x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
HINDBIO Cash Flow Quality — Operating & Free Cash Flow
Hindustan Bio Sciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |